Literature DB >> 22369501

Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure.

Nitya Nathwani, Amrita Y Krishnan, Qin Huang, Young Kim, Chatchada Karanes, Eileen P Smith, Stephen J Forman, Eric Sievers, Sandra H Thomas, Robert W Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22369501      PMCID： PMC3808117          DOI： 10.3109/10428194.2012.666543

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  12 in total

1.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Authors:  Norbert Schmitz; Beate Pfistner; Michael Sextro; Markus Sieber; Angelo M Carella; Matthias Haenel; Friederike Boissevain; Reinhart Zschaber; Peter Müller; Hartmut Kirchner; Andreas Lohri; Susanne Decker; Bettina Koch; Dirk Hasenclever; Anthony H Goldstone; Volker Diehl
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

2.  Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells.

Authors:  M A Ghetie; V Ghetie; E S Vitetta
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

Review 3.  Microtubules and resistance to tubulin-binding agents.

Authors:  Maria Kavallaris
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

4.  Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease.

Authors:  A R Yuen; S A Rosenberg; R T Hoppe; J D Halpern; S J Horning
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

5.  Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin.

Authors:  Pei Pei Gan; Joshua A McCarroll; Sela T Po'uha; Kathy Kamath; Mary Ann Jordan; Maria Kavallaris
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

Review 6.  From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential.

Authors:  Daniel Re; Roman K Thomas; Karolin Behringer; Volker Diehl
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

Review 7.  CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.

Authors:  B Falini; S Pileri; G Pizzolo; H Dürkop; L Flenghi; F Stirpe; M F Martelli; H Stein
Journal:  Blood       Date:  1995-01-01       Impact factor: 22.113

8.  Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.

Authors:  Robert Chen; Joycelynne M Palmer; Leslie Popplewell; Jessica Shen; Eileen Smith; Maria Delioukina; Neil Kogut; Joseph Rosenthal; Stephen Forman; Auayporn Nademanee
Journal:  Ann Hematol       Date:  2011-01-06       Impact factor: 3.673

9.  Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.

Authors:  Paolo Anderlini; Rima Saliba; Sandra Acholonu; Sergio A Giralt; Borje Andersson; Naoto T Ueno; Chitra Hosing; Issa F Khouri; Daniel Couriel; Marcos de Lima; Muzaffar H Qazilbash; Barbara Pro; Jorge Romaguera; Luis Fayad; Frederick Hagemeister; Anas Younes; Mark F Munsell; Richard E Champlin
Journal:  Haematologica       Date:  2008-01-26       Impact factor: 9.941

10.  Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Anna Sureda; Stephen Robinson; Carmen Canals; Angelo M Carella; Marc A Boogaerts; Dolores Caballero; Ann E Hunter; Lothar Kanz; Shimon Slavin; Jan J Cornelissen; Martin Gramatzki; Dietger Niederwieser; Nigel H Russell; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2007-12-17       Impact factor: 44.544
View more
  9 in total

1.  Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.

Authors:  Shinichi Makita; Akiko Miyagi Maeshima; Hirokazu Taniguchi; Hideaki Kitahara; Suguru Fukuhara; Wataru Munakata; Tatsuya Suzuki; Dai Maruyama; Yukio Kobayashi; Kensei Tobinai
Journal:  Int J Hematol       Date:  2016-05-12       Impact factor: 2.490

2.  CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.

Authors:  Robert Chen; Jessie Hou; Edward Newman; Young Kim; Cecile Donohue; Xueli Liu; Sandra H Thomas; Stephen J Forman; Susan E Kane
Journal:  Mol Cancer Ther       Date:  2015-04-03       Impact factor: 6.261

3.  A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.

Authors:  Jason Gotlib; John H Baird; Tracy I George; Cheryl Langford; Isabel Reyes; Justin Abuel; Cecelia Perkins; Kurt Schroeder; Prithviraj Bose; Srdan Verstovsek
Journal:  Blood Adv       Date:  2019-08-13

Review 4.  Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.

Authors:  Matthew Mei; Sandra Thomas; Robert Chen
Journal:  BioDrugs       Date:  2014-06       Impact factor: 5.807

Review 5.  Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.

Authors:  Solomon A Graf; Ajay K Gopal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

6.  A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.

Authors:  Jacqueline N Poston; Jonathan R Fromm; Heather A Rasmussen; Andrei R Shustov; Edward N Libby; Stephen D Smith; Ted Gooley; Ajay K Gopal
Journal:  Br J Haematol       Date:  2018-12-28       Impact factor: 6.998

Review 7.  Novel CD20 monoclonal antibodies for lymphoma therapy.

Authors:  Shundong Cang; Nikhil Mukhi; Kemeng Wang; Delong Liu
Journal:  J Hematol Oncol       Date:  2012-10-11       Impact factor: 17.388

8.  A CD205-directed antibody drug conjugate - lymphoma precision oncology or sophisticated chemotherapy?

Authors:  Damian T Rieke; Ulrich Keller
Journal:  Haematologica       Date:  2020-11-01       Impact factor: 9.941

Review 9.  Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

Authors:  C A van der Weyden; S A Pileri; A L Feldman; J Whisstock; H M Prince
Journal:  Blood Cancer J       Date:  2017-09-08       Impact factor: 11.037
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.